FilingReader Intelligence
SSY Group wins China drug approval for cholesterol treatment
July 28, 2025 at 04:09 AM UTC•By FilingReader AI
SSY Group Limited announced approval from China's National Medical Products Administration for production and registration of Rosuvastatin Calcium and Ezetimibe Tablets (10mg).
The approval represents the third such approval for the company's PRC entities. The drug treats primary hypercholesterolemia, mixed hyperlipidemia in adults, and homozygous familial hypercholesterolemia alongside diet control.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
HKEX:2005•Hong Kong Exchange
News Alerts
Get instant email alerts when SSY Group publishes news
Free account required • Unsubscribe anytime